Peptron enters into co-research agreement with swiss-based Debiopharm on next-generation ADCs, validating the broader potential of PAb001. Thursday, June 25, 2026 Peptron (087010), an innovative peptide-based drug development company, announced that it has entered into a co-research agreement with Debiopharm (Debiopharm Research & Manufacturing SA),, a Swiss-based global biopharmaceutical company, to develop next-generation antibody-drug conjugates (ADCs) using Peptron's Mucin 1 (MUC1)-targeting antibody, PAb001. The collaboration aims to discover and evaluate multiple PAb001-based ADC candidates by combining Peptron's PAb001 antibody with Debiopharm's proprietary ADC platform technology, MultiLINK(TM). PAb001 is an antibody targeting MUC1, which is expressed in various solid tumors. Based on its strong tumor-targeting properties, PAb001 is regarded as a promising antibody asset that may be applicable to the development of various oncology modalities, including ADCs. Under the research collaboration, Debiopharm will design and produce multiple PAb001-ADC candidates using its MultiLINK(TM) platform, which integrates cytotoxic payloads, linkers connecting antibodies and payloads, and conjugation technologies. Peptron plans to conduct in vitro efficacy evaluations, in vivo antitumor efficacy studies, and pharmacokinetic (PK) studies on the ADC candidates provided by Debiopharm. Through these studies, Peptron will compare the characteristics of each candidate and conduct research to support the selection of an optimal development candidate. Rather than focusing on the development of a single ADC candidate, the two companies plan to evaluate various combinations of linkers, payloads, and conjugation technologies. Through this approach, they aim to expand the applicability and development potential of the PAb001 antibody in ADCs and secure diverse follow-on development options. Founded in 1979, Debiopharm is a Swiss-based global biopharmaceutical company with experience in developing oncology and specialty pharmaceutical products, including oxaliplatin and triptorelin. Debiopharm has recently been expanding its activities in the ADC field, including a growing pipeline of potential first-in-class and best-in-class compounds Debiopharm also has a proprietary ADC platform, MultiLINK(TM), which supports various linker and payload combinations and includes dual-payload ADC technology that enables two different payloads to be conjugated to a single antibody. The platform is characterized by its flexibility in ADC design, based on its high compatibility with diverse payloads and conjugation methods. "PAb001 is an antibody asset that enables a wide range of ADC designs based on its strong tumor-targeting properties," said Ho-il Choi, CEO of Peptron. "We expect this research collaboration to further enhance the versatility and commercialization potential of PAb001 by applying various linker, payload, and conjugation technologies beyond the development of a single specific ADC candidate." He added, "Debiopharm's MultiLINK(TM) platform is recognized as a next-generation technology capable of providing diverse ADC design options. Through this research, we plan to secure multiple PAb001-based ADC candidates and establish a foundation for future expansion into various oncology pipelines." Debiopharm CSO Frederic Levy also commented, "We are pleased to evaluate various ADC design possibilities by combining PAb001, which has promising characteristics, with Debiopharm's MultiLINK(TM) platform." ADCs are next-generation anticancer therapeutic technologies that combine the tumor selectivity of antibodies with cytotoxic drugs. They are regarded as one of the fastest-growing fields in the global biopharmaceutical industry. Recently, active development efforts have been underway for next-generation ADC technologies utilizing multiple payloads, moving beyond conventional single-payload approaches. Debiopharm's ADC Expertise Debiopharm is developing fit-for-purpose antibody-drug conjugates through a tailored "Trifecta" approach: strategic target selection, innovative proprietary MultiLINK(TM) linker technology, and smart payload choices. Their ADC portfolio includes first-in-class or best-in-class candidates: the clinical-stage Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and Debio 2512, targeting HER3 & HER2 driven cancers, as well as other ADCs with undisclosed targets. They are actively partnering to access innovative targets, co-develop, or out-license its ADC programs and linker technologies. Their strong in-house capabilities and in-depth expertise span across ADC conjugation and optimization, pharmacokinetics/ pharmacodynamics (PK/PD), toxicology, translational, pharmaceutical (CMC) and clinical development, and supply chain management. They continue to invest in and explore potential game-changing technologies, such as novel and dual payloads. Contacts Debiopharm Dawn Haughton-Bonine Head of Communications Tel: +41 (0)21 321 01 11

Minerva Imaging and Debiopharm partner with enabling conjugation technology to advance next generation radiopharmaceuticals. Olstykke, Denmark and Martigny, Switzerland - May 29, 2026 - Minerva Imaging, a market-leading, integrated Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CDMO) specialized in targeted radioligand therapies, today announced a strategic collaboration with Debiopharm, a Swiss-based biopharmaceutical company focused on the development of innovative therapies in oncology and infectious diseases. The collaboration centers around the integration of Debiopharm's proprietary AbYlink(TM) conjugation technology into Minerva Imaging's preclinical research platform, supporting the development of next-generation radiopharmaceuticals as well as other targeted conjugates. AbYlink(TM) enables one step regio-selective conjugation of a variety of payloads on the Fc domain of antibodies without affecting antigen-binding domains. Under the license agreement, Minerva Imaging will apply the technology to the development of theranostics, and emerging biologic-based radiopharmaceutical formats. For Minerva Imaging's customers, the addition of AbYlink(TM) expands the toolbox available for designing more precise and better-characterized targeted agents. The technology can support evaluation of biological vectors such as antibodies, antibody drug conjugates, antibody fragments, and other Fc-containing molecules for delivery of radioisotopes or other payloads, while preserving target binding and enabling more controlled construct design during discovery and translational development. The collaboration also reflects a broader evolution in radiopharmaceutical development, as the field expands beyond small molecules and peptides towards more complex biological vectors that may offer differentiated targeting, pharmacokinetics, and payload flexibility. By incorporating AbYlink(TM) into its integrated platform, Minerva Imaging is positioned to support customers developing these next-generation approaches from early concept evaluation through translational studies and manufacturing readiness. "Radiopharmaceuticals are rapidly transforming oncology, and at Minerva Imaging we are at the forefront of the developments." said Carsten H. Nielsen, CEO and Co-founder of Minerva Imaging. "With the integration of AbYlink(TM) into our capabilities, we further strengthen our fully integrated radiopharmaceutical platform. Importantly, this gives our customers new opportunities to evaluate biologically derived targeting vectors and develop more advanced, precisely engineered radiopharmaceuticals and conjugates across the drug development pathway." "Debiopharm is pleased to collaborate with Minerva Imaging to broaden the application of AbYlink(TM) in targeted therapeutic development," said Frederic Levy, Chief Scientific Officer, Debiopharm. "By combining Debiopharm's conjugation technology with Minerva Imaging's radiopharmaceutical research and development capabilities, this collaboration has the potential to accelerate innovation in next-generation targeted therapies." About Minerva Imaging Minerva Imaging is a fully integrated CRO and CDMO specialized in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best-in-industry fully integrated radiopharmaceutical research, drug development and manufacturing services. Minerva's competences are built on over 25 years of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark. Follow Minerva Imaging on LinkedIn for the latest news updates or visit www.minervaimaging.com for more information. About Debiopharm Debiopharm is a privately owned, Swiss-based biopharmaceutical company with the ambition to develop therapies that cure cancer and infectious diseases. Minerva Imaging ApS identify high-potential compounds and technologies for in licensing, drive programs through translational medicine and clinical development milestones, to then and then select international pharmaceutical partners for commercialization. Through collaboration with other radioligand therapy expert organisations, Minerva Imaging ApS seek to accelerate innovation that helps patients live longer. About AbYlink(TM) AbYlink(TM) is a versatile and rapid regio-selective chemical conjugation technology for use in preparing diagnostic or therapeutic conjugates. This one step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. AbYlink is a registered trademark of Debiopharm International SA Media Contacts: Fabian Pruissen Senior Business Developer [email protected] Dawn Bonine Head of Communications [email protected]

ViewsML raises $4.9M for ai-driven virtual biomarker staining platform. HIT Consultant April 21, 2026 Fred Pennic What You Should Know * The Funding: ViewsML, a company building the computational layer for biomarker discovery, has closed an oversubscribed $4.9M seed round led by Wittington Ventures, with significant strategic participation from Mayo Clinic and Continuum Health Ventures, alongside repeat investors like RiSC Capital and Debiopharm. * The Core Technology: ViewsML is building the world's first virtual biomarker library. Using artificial intelligence, the platform generates per-cell biomarker spatial insights directly from standard, routine pathology images (H&E slides) - completely eliminating the need for physical laboratory staining (immunohistochemistry or IHC). * The Next Steps: The capital will be used to accelerate the commercialization of the platform, advance clinical validation, and expand engineering teams. ViewsML will publicly showcase the technology at the American Association for...